Skip to main content
Erschienen in: Tumor Biology 2/2013

01.04.2013 | Research Article

Zebularine-induced apoptosis in Calu-6 lung cancer cells is influenced by ROS and GSH level changes

verfasst von: Bo Ra You, Woo Hyun Park

Erschienen in: Tumor Biology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Zebularine (Zeb) is a DNA methyltransferase (DNMT) inhibitor that has various biological properties including anti-cancer effect. In the present study, we evaluated the effects of Zeb on the growth and death of Calu-6 lung cancer cells in relation to reactive oxygen species (ROS) and glutathione (GSH) levels. Zeb inhibited the growth of Calu-6 cells with an IC50 of approximately 150 μM at 72 h in a dose-dependent manner. Zeb induced an S phase arrest of the cell cycle and apoptosis in Calu-6 cells. Pan-caspase inhibitor (Z-VAD) and caspase-8 inhibitor (Z-IETD) significantly rescued some cells from Zeb-induced Calu-6 cell death. In relation to ROS and GSH levels, O2 •− level was significantly increased in Zeb-treated Calu-6 cells and caspase inhibitors reduced O2 •− level in these cells. Zeb induced GSH depletion in HeLa cells, which was attenuated by caspase inhibitors. L-buthionine sulfoximine (BSO), a GSH synthesis inhibitor, intensified the apoptotic cell death, ROS level, and GSH depletion in Zeb-treated Calu-6 cells. In addition, BSO increased Bax protein and decreased Bcl-2 protein in Zeb-treated Calu-6 cells. In conclusion, Zeb inhibited the growth of Calu-6 lung cancer cells via cell cycle arrest and caspase-dependent apoptosis and its cell death was influenced by ROS and GSH level changes.
Literatur
1.
Zurück zum Zitat Lee JY, Lee TH. Effects of DNA methylation on the structure of nucleosomes. J Am Chem Soc. 2012;134:173–5.PubMedCrossRef Lee JY, Lee TH. Effects of DNA methylation on the structure of nucleosomes. J Am Chem Soc. 2012;134:173–5.PubMedCrossRef
2.
Zurück zum Zitat Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, et al. General transcription factor binding at cpg islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res. 2010;70:1398–407.PubMedCrossRef Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, et al. General transcription factor binding at cpg islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res. 2010;70:1398–407.PubMedCrossRef
3.
Zurück zum Zitat Takeshima H, Yamashita S, Shimazu T, Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter cpg islands to aberrant DNA methylation induction. Genomics. 2011;98:182–8.PubMedCrossRef Takeshima H, Yamashita S, Shimazu T, Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter cpg islands to aberrant DNA methylation induction. Genomics. 2011;98:182–8.PubMedCrossRef
4.
Zurück zum Zitat Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, et al. Zic1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One. 2011;6:e16916.PubMedCrossRef Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, et al. Zic1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One. 2011;6:e16916.PubMedCrossRef
5.
Zurück zum Zitat Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen nnk induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. 2010;120:521–32.PubMedCrossRef Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen nnk induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. 2010;120:521–32.PubMedCrossRef
6.
Zurück zum Zitat Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011;21:1017–27.PubMedCrossRef Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 2011;21:1017–27.PubMedCrossRef
7.
Zurück zum Zitat Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA. Role of the DNA methyltransferase variant dnmt3b3 in DNA methylation. Molecular cancer research: MCR. 2004;2:62–72.PubMed Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA. Role of the DNA methyltransferase variant dnmt3b3 in DNA methylation. Molecular cancer research: MCR. 2004;2:62–72.PubMed
8.
Zurück zum Zitat Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X, et al. Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol. 2010;134:826–34.PubMedCrossRef Qu Y, Mu G, Wu Y, Dai X, Zhou F, Xu X, et al. Overexpression of DNA methyltransferases 1, 3a, and 3b significantly correlates with retinoblastoma tumorigenesis. Am J Clin Pathol. 2010;134:826–34.PubMedCrossRef
9.
Zurück zum Zitat Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M. DNA methyltransferase dnmt3b protein overexpression as a prognostic factor in patients with diffuse large b-cell lymphomas. Cancer Sci. 2010;101:1722–30.PubMedCrossRef Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M. DNA methyltransferase dnmt3b protein overexpression as a prognostic factor in patients with diffuse large b-cell lymphomas. Cancer Sci. 2010;101:1722–30.PubMedCrossRef
10.
Zurück zum Zitat Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305.PubMedCrossRef Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305.PubMedCrossRef
11.
Zurück zum Zitat Lim SP, Neilsen P, Kumar R, Abell A, Callen DF. The application of delivery systems for DNA methyltransferase inhibitors. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011;25:227–42.CrossRef Lim SP, Neilsen P, Kumar R, Abell A, Callen DF. The application of delivery systems for DNA methyltransferase inhibitors. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2011;25:227–42.CrossRef
12.
Zurück zum Zitat Gore SD. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011;2011:550–5.PubMedCrossRef Gore SD. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011;2011:550–5.PubMedCrossRef
13.
Zurück zum Zitat Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2009;23:1019–28.CrossRef Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2009;23:1019–28.CrossRef
14.
Zurück zum Zitat Savickiene J, Treigyte G, Jonusiene V, Bruzaite R, Borutinskaite VV, Navakauskiene R. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia nb4 and kg1 cells. Mol Cell Biochem. 2012;359:245–61.PubMedCrossRef Savickiene J, Treigyte G, Jonusiene V, Bruzaite R, Borutinskaite VV, Navakauskiene R. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia nb4 and kg1 cells. Mol Cell Biochem. 2012;359:245–61.PubMedCrossRef
15.
Zurück zum Zitat Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, et al. Inhibition of DNA methyltransferase induces g2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of jak2/stat3/stat5 signalling. J Cell Mol Med. 2009;13:3668–79.PubMedCrossRef Xiong H, Chen ZF, Liang QC, Du W, Chen HM, Su WY, et al. Inhibition of DNA methyltransferase induces g2 cell cycle arrest and apoptosis in human colorectal cancer cells via inhibition of jak2/stat3/stat5 signalling. J Cell Mol Med. 2009;13:3668–79.PubMedCrossRef
16.
Zurück zum Zitat Cui M, Wen Z, Chen J, Yang Z, Zhang H. 5-aza-2′-deoxycytidine is a potent inhibitor of DNA methyltransferase 3b and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hmlh1. Med Oncol. 2010;27:278–85.PubMedCrossRef Cui M, Wen Z, Chen J, Yang Z, Zhang H. 5-aza-2′-deoxycytidine is a potent inhibitor of DNA methyltransferase 3b and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hmlh1. Med Oncol. 2010;27:278–85.PubMedCrossRef
17.
Zurück zum Zitat Vivaldi A, Miasaki FY, Ciampi R, Agate L, Collecchi P, Capodanno A, et al. Re-differentiation of thyroid carcinoma cell lines treated with 5-aza-2′-deoxycytidine and retinoic acid. Mol Cell Endocrinol. 2009;307:142–8.PubMedCrossRef Vivaldi A, Miasaki FY, Ciampi R, Agate L, Collecchi P, Capodanno A, et al. Re-differentiation of thyroid carcinoma cell lines treated with 5-aza-2′-deoxycytidine and retinoic acid. Mol Cell Endocrinol. 2009;307:142–8.PubMedCrossRef
18.
Zurück zum Zitat Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of ms-275 and 5-azacytidine in leukemic cells. Leuk Res. 2008;32:771–80.PubMedCrossRef Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of ms-275 and 5-azacytidine in leukemic cells. Leuk Res. 2008;32:771–80.PubMedCrossRef
19.
Zurück zum Zitat You BR, Park WH: Zebularine inhibits the growth of hela cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis. Molecular biology reports 2012 You BR, Park WH: Zebularine inhibits the growth of hela cervical cancer cells via cell cycle arrest and caspase-dependent apoptosis. Molecular biology reports 2012
20.
Zurück zum Zitat Bogurcu N, Sevimli-Gur C, Ozmen B, Bedir E, Korkmaz KS. Alcaps induce mitochondrial apoptosis and activate DNA damage response by generating ros and inhibiting topoisomerase i enzyme activity in k562 leukemia cell line. Biochem Biophys Res Commun. 2011;409:738–44.PubMedCrossRef Bogurcu N, Sevimli-Gur C, Ozmen B, Bedir E, Korkmaz KS. Alcaps induce mitochondrial apoptosis and activate DNA damage response by generating ros and inhibiting topoisomerase i enzyme activity in k562 leukemia cell line. Biochem Biophys Res Commun. 2011;409:738–44.PubMedCrossRef
21.
Zurück zum Zitat Ravindran J, Gupta N, Agrawal M. Bala Bhaskar AS, Lakshmana Rao PV: Modulation of ros/mapk signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis: an international journal on programmed cell death. 2011;16:145–61.CrossRef Ravindran J, Gupta N, Agrawal M. Bala Bhaskar AS, Lakshmana Rao PV: Modulation of ros/mapk signaling pathways by okadaic acid leads to cell death via, mitochondrial mediated caspase-dependent mechanism. Apoptosis: an international journal on programmed cell death. 2011;16:145–61.CrossRef
22.
Zurück zum Zitat Wagner KW, Ye Y, Lin J, Vaporciyan AA, Roth JA, Wu X. Genetic variations in epigenetic genes are predictors of recurrence in stage i or ii non-small cell lung cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18:585–92.CrossRef Wagner KW, Ye Y, Lin J, Vaporciyan AA, Roth JA, Wu X. Genetic variations in epigenetic genes are predictors of recurrence in stage i or ii non-small cell lung cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18:585–92.CrossRef
23.
Zurück zum Zitat Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:645–54.CrossRef Feng Q, Hawes SE, Stern JE, Wiens L, Lu H, Dong ZM, et al. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:645–54.CrossRef
24.
Zurück zum Zitat Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865–77.PubMedCrossRef Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865–77.PubMedCrossRef
25.
Zurück zum Zitat Kouidou S, Agidou T, Kyrkou A, Andreou A, Katopodi T, Georgiou E, et al. Non-cpg cytosine methylation of p53 exon 5 in non-small cell lung carcinoma. Lung Cancer. 2005;50:299–307.PubMedCrossRef Kouidou S, Agidou T, Kyrkou A, Andreou A, Katopodi T, Georgiou E, et al. Non-cpg cytosine methylation of p53 exon 5 in non-small cell lung carcinoma. Lung Cancer. 2005;50:299–307.PubMedCrossRef
26.
Zurück zum Zitat Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010;120:581–92.PubMedCrossRef Billam M, Sobolewski MD, Davidson NE. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat. 2010;120:581–92.PubMedCrossRef
27.
Zurück zum Zitat Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med. 2010;2:54ra77.PubMedCrossRef Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, et al. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med. 2010;2:54ra77.PubMedCrossRef
28.
Zurück zum Zitat Park WH, Han YH, Kim SH, Kim SZ. Pyrogallol, ros generator inhibits as4.1 juxtaglomerular cells via cell cycle arrest of g2 phase and apoptosis. Toxicology. 2007;235:130–9.PubMedCrossRef Park WH, Han YH, Kim SH, Kim SZ. Pyrogallol, ros generator inhibits as4.1 juxtaglomerular cells via cell cycle arrest of g2 phase and apoptosis. Toxicology. 2007;235:130–9.PubMedCrossRef
29.
Zurück zum Zitat Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits growth of as4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am J Physiol Renal Physiol. 2007;293:F511–20.PubMedCrossRef Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits growth of as4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. Am J Physiol Renal Physiol. 2007;293:F511–20.PubMedCrossRef
30.
Zurück zum Zitat Han YH, Kim SH, Kim SZ, Park WH. Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer calu-6 cells via the prevention of gsh depletion. Int J Oncol. 2008;33:1099–105.PubMed Han YH, Kim SH, Kim SZ, Park WH. Caspase inhibitor decreases apoptosis in pyrogallol-treated lung cancer calu-6 cells via the prevention of gsh depletion. Int J Oncol. 2008;33:1099–105.PubMed
31.
Zurück zum Zitat You BR, Park WH. Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicology in vitro: an international journal published in association with BIBRA. 2010;24:1356–62.CrossRef You BR, Park WH. Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase. Toxicology in vitro: an international journal published in association with BIBRA. 2010;24:1356–62.CrossRef
32.
Zurück zum Zitat Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004;24:1270–8.PubMedCrossRef Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol. 2004;24:1270–8.PubMedCrossRef
33.
Zurück zum Zitat Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, et al. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther. 2012;11:370–82.PubMedCrossRef Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, et al. DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther. 2012;11:370–82.PubMedCrossRef
34.
Zurück zum Zitat Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of apo2l/trail receptor 1 (dr4) expression overcomes resistance of sk-mel-3 and sk-mel-28 melanoma cells to interferons (ifns) or apo2l/trail. Oncogene. 2008;27:490–8.PubMedCrossRef Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of apo2l/trail receptor 1 (dr4) expression overcomes resistance of sk-mel-3 and sk-mel-28 melanoma cells to interferons (ifns) or apo2l/trail. Oncogene. 2008;27:490–8.PubMedCrossRef
35.
Zurück zum Zitat Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ros) control the expression of bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004;95:644–50.PubMedCrossRef Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ros) control the expression of bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004;95:644–50.PubMedCrossRef
36.
Zurück zum Zitat Chaudhari AA, Seol JW, Kim SJ, Lee YJ, Kang HS, Kim IS, et al. Reactive oxygen species regulate bax translocation and mitochondrial transmembrane potential, a possible mechanism for enhanced trail-induced apoptosis by cccp. Oncol Rep. 2007;18:71–6.PubMed Chaudhari AA, Seol JW, Kim SJ, Lee YJ, Kang HS, Kim IS, et al. Reactive oxygen species regulate bax translocation and mitochondrial transmembrane potential, a possible mechanism for enhanced trail-induced apoptosis by cccp. Oncol Rep. 2007;18:71–6.PubMed
37.
Zurück zum Zitat Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000;89:1440–7.PubMedCrossRef Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000;89:1440–7.PubMedCrossRef
Metadaten
Titel
Zebularine-induced apoptosis in Calu-6 lung cancer cells is influenced by ROS and GSH level changes
verfasst von
Bo Ra You
Woo Hyun Park
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0656-8

Weitere Artikel der Ausgabe 2/2013

Tumor Biology 2/2013 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.